CN104704368A - 肿瘤细胞分离/纯化方法和其使用方法 - Google Patents

肿瘤细胞分离/纯化方法和其使用方法 Download PDF

Info

Publication number
CN104704368A
CN104704368A CN201380037542.XA CN201380037542A CN104704368A CN 104704368 A CN104704368 A CN 104704368A CN 201380037542 A CN201380037542 A CN 201380037542A CN 104704368 A CN104704368 A CN 104704368A
Authority
CN
China
Prior art keywords
drug candidate
anticancer drug
cell
drug
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380037542.XA
Other languages
English (en)
Chinese (zh)
Inventor
C·普莱森特
M·派瑞
A·哈尔奎斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diatech Oncology LLC
Original Assignee
Diatech Oncology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diatech Oncology LLC filed Critical Diatech Oncology LLC
Publication of CN104704368A publication Critical patent/CN104704368A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/24—Methods of sampling, or inoculating or spreading a sample; Methods of physically isolating an intact microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/557—Immunoassay; Biospecific binding assay; Materials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2527/00—Culture process characterised by the use of mechanical forces, e.g. strain, vibration
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380037542.XA 2012-05-15 2013-03-14 肿瘤细胞分离/纯化方法和其使用方法 Pending CN104704368A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647248P 2012-05-15 2012-05-15
US61/647,248 2012-05-15
PCT/US2013/031300 WO2013172955A1 (en) 2012-05-15 2013-03-14 Tumor cell isolation/purification process and methods for use thereof

Publications (1)

Publication Number Publication Date
CN104704368A true CN104704368A (zh) 2015-06-10

Family

ID=49584132

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380037542.XA Pending CN104704368A (zh) 2012-05-15 2013-03-14 肿瘤细胞分离/纯化方法和其使用方法

Country Status (17)

Country Link
US (2) US20150160193A1 (enExample)
EP (1) EP2850434A4 (enExample)
JP (1) JP2015517662A (enExample)
KR (1) KR20150035537A (enExample)
CN (1) CN104704368A (enExample)
AU (1) AU2013263337A1 (enExample)
BR (1) BR112014028396A2 (enExample)
CA (1) CA2873180A1 (enExample)
CO (1) CO7240391A2 (enExample)
CR (1) CR20140575A (enExample)
HK (1) HK1208727A1 (enExample)
IL (1) IL235709A0 (enExample)
IN (1) IN2014DN09582A (enExample)
MX (1) MX2014013939A (enExample)
SG (1) SG11201407497TA (enExample)
TW (1) TW201409029A (enExample)
WO (1) WO2013172955A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384790A (zh) * 2018-03-20 2021-02-19 路玛赛特有限责任公司 利用激光力细胞学的改进生物物理和生物化学细胞监测和定量

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12324657B2 (en) 2007-11-28 2025-06-10 Intervet Inc. System and method for diagnosis of bovine diseases using auscultation analysis
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
EP2953544B1 (en) * 2013-02-06 2019-05-08 Intervet Inc. System for determining antibiotic effectiveness in respiratory diseased using auscultation analysis
MY189089A (en) 2013-12-17 2022-01-25 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
CN116327953A (zh) 2015-06-17 2023-06-27 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
EP3423105B1 (en) 2016-03-02 2021-05-05 Eisai R&D Management Co., Ltd. Eribulin-based antibody-drug conjugates and methods of use
TWI662130B (zh) * 2018-09-21 2019-06-11 國立臺灣大學 分離循環癌細胞之方法
CN111019899B (zh) * 2019-02-14 2023-08-04 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系lj-0429及其应用
CN111019897B (zh) * 2019-02-14 2023-08-11 中山大学孙逸仙纪念医院 人良性叶状肿瘤细胞系glk-1010及其应用
CN111019898B (zh) * 2019-02-14 2023-07-21 中山大学孙逸仙纪念医院 人恶性叶状肿瘤细胞系hjp-0320及其应用
CN113466417B (zh) * 2021-05-13 2023-03-21 柳州东风容泰化工股份有限公司 一种氟尿嘧啶的制备纯度评估方法及系统
WO2024054627A1 (en) * 2022-09-08 2024-03-14 The University Of North Carolina At Chapel Hill Diagnosis of patient tumor tissue
CN115747290A (zh) * 2022-11-23 2023-03-07 零壹人工智能科技研究院(南京)有限公司 一种对肠癌类器官进行药敏测试的新操作方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1221492A (zh) * 1996-04-05 1999-06-30 约翰斯·霍普金斯大学 富集稀少细胞的方法
WO2010052543A1 (en) * 2008-11-04 2010-05-14 Silicon Biosystems S.P.A. Method for identification, selection and analysis of tumour cells
WO2011123103A1 (en) * 2010-03-31 2011-10-06 Diatech Oncology, Llc System and method for anti-cancer drug candidate evaluation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077684A (en) * 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
WO2002040702A2 (en) * 2000-11-09 2002-05-23 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
KR100721927B1 (ko) * 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1221492A (zh) * 1996-04-05 1999-06-30 约翰斯·霍普金斯大学 富集稀少细胞的方法
WO2010052543A1 (en) * 2008-11-04 2010-05-14 Silicon Biosystems S.P.A. Method for identification, selection and analysis of tumour cells
WO2011123103A1 (en) * 2010-03-31 2011-10-06 Diatech Oncology, Llc System and method for anti-cancer drug candidate evaluation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAREN S. BALLARD 等: "Endometrial carcinoma in vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic apoptosis assay: implications for endometrial cancer treatment", 《J GYNECOL ONCOL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384790A (zh) * 2018-03-20 2021-02-19 路玛赛特有限责任公司 利用激光力细胞学的改进生物物理和生物化学细胞监测和定量

Also Published As

Publication number Publication date
WO2013172955A9 (en) 2014-02-27
SG11201407497TA (en) 2014-12-30
AU2013263337A1 (en) 2014-12-04
CR20140575A (es) 2015-05-07
CO7240391A2 (es) 2015-04-17
BR112014028396A2 (pt) 2018-05-29
TW201409029A (zh) 2014-03-01
EP2850434A4 (en) 2016-01-13
CA2873180A1 (en) 2013-11-21
WO2013172955A1 (en) 2013-11-21
US20170336391A1 (en) 2017-11-23
JP2015517662A (ja) 2015-06-22
HK1208727A1 (zh) 2016-03-11
MX2014013939A (es) 2015-05-11
IN2014DN09582A (enExample) 2015-07-17
EP2850434A1 (en) 2015-03-25
US20150160193A1 (en) 2015-06-11
IL235709A0 (en) 2015-01-29
KR20150035537A (ko) 2015-04-06

Similar Documents

Publication Publication Date Title
CN104704368A (zh) 肿瘤细胞分离/纯化方法和其使用方法
Lin et al. Circulating tumor cells: biology and clinical significance
Izar et al. A single-cell landscape of high-grade serous ovarian cancer
Yu et al. Dual tumor exosome biomarker co-recognitions based nanoliquid biopsy for the accurate early diagnosis of pancreatic cancer
Huang et al. Gelatin nanoparticle-coated silicon beads for density-selective capture and release of heterogeneous circulating tumor cells with high purity
Gomes et al. ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation
Kolostova et al. Circulating tumor cells in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score
Lu et al. The expression of V-ATPase is associated with drug resistance and pathology of non-small-cell lung cancer
CN109563486A (zh) 用于在癌症护理中做出患者特定的治疗决策的诊断方法
US20230184744A1 (en) INTERTUMORAL HOMOGENEITY DETERMINED BY MiCK ASSAY
JP2018052956A (ja) 低酸素活性化プロドラッグ療法のための予測バイオマーカー
Lu et al. Evaluation of a new magnetic bead as an integrated platform for systematic CTC recognition, capture and clinical analysis
Yin et al. Liquid biopsies in cancer
Zafar et al. Emerging biomarkers for early cancer detection and diagnosis: Challenges, innovations, and clinical perspectives
Gao et al. Single-cell RNA sequencing in double-hit lymphoma: IMPDH2 induces the progression of lymphoma by activating the PI3K/AKT/mTOR signaling pathway
Corinaldesi et al. Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistance
EP4321868A1 (en) Method for treating cancer using immune checkpoint inhibitor
Shao et al. Exosomal miR-92a-3p serves as a promising marker and potential therapeutic target for adenomyosis
Tataranu Liquid biopsy as a diagnostic and monitoring tool in glioblastoma
Li et al. Exosomal miRNA-188-3p derived from cancer-associated fibroblasts promotes ferroptosis in cervical cancer: Medical Biothermal Image Analysis
Wang et al. ALK-positive large B-cell lymphoma: a clinicopathological and molecular characteristics analysis of seven cases
Katole et al. Unraveling the Landscape of Pediatric Glioblastoma Biomarkers: A Comprehensive Review of Enhancing Diagnostics and Therapeutic Insights
Morad et al. Microbial signals in primary and metastatic brain tumors
Niu Monitoring and Targeting Metastasis Through Circulating Tumor Cells: From Molecular Profiling to Natural Killer Cell-Based Therapeutics
Shibuta et al. miR-494 in Extracellular Vesicles as a Potent Biomarker of Chronic Myeloid Leukemia Treatment with Tyrosine Kinase Inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150610